Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/5/2025

Treatment of Bipolar II Disorder

First-Line Treatment Options

  • Valproate shows higher response rates (53%) compared to lithium (38%) in treating bipolar disorder, though most studies don't specifically differentiate bipolar II 1
  • Quetiapine plus valproate is more effective than valproate alone for bipolar disorder 1
  • Other atypical antipsychotics (aripiprazole, olanzapine, risperidone, ziprasidone) are approved for acute mania but have less specific evidence for bipolar II 1

Treatment Algorithm Based on Predominant Symptoms

  • For patients with predominant depression, lamotrigine is started at a low dose with gradual titration to minimize risk of serious rash, with a target dose of 200mg daily 2

Important Clinical Considerations

  • Antidepressant monotherapy should be avoided as it can trigger hypomania, rapid cycling, or mood destabilization 1
  • Regular monitoring is essential for lithium, including thyroid function, renal function, and serum levels 1
  • Regular monitoring is also essential for atypical antipsychotics, including metabolic parameters (weight, lipids, glucose) 1

Special Considerations for Bipolar II

  • Maintenance therapy is often needed for extended periods, with some individuals requiring lifelong therapy 2

Common Pitfalls to Avoid

  • Inadequate duration of maintenance therapy can result in high relapse rates 1
  • Failure to monitor for medication-specific side effects, particularly metabolic effects of atypical antipsychotics and skin reactions with lamotrigine 1
  • Overlooking comorbidities that may complicate treatment response 1

REFERENCES

1

First-Line Treatment of Bipolar Disorder [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

2

practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. [LINK]

Journal of the American Academy of Child and Adolescent Psychiatry, 2007